Inventor

Anthony Cerami

Inventor

Shelter Island, NY, US

Overview

1981–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 172 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes22%

G01NInvestigating or analysing materials by determining their chemical or physical properties15%

C07KPeptides14%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations10%

C07DHeterocyclic compounds9%

A61QSpecific use of cosmetics or similar toiletry preparations9%

C12NMicroorganisms or enzymes5%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4%

Y02ATechnologies for adaptation to climate change3%

C07CAcyclic or carbocyclic compounds3%

PatentTitleYear

10,864,253Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage2020 10,539,563Anti-carbamylated protein antibodies and the risk for arthritis2020 10,100,096Tissue protective peptides and uses thereof2018 10,078,080Anti-carbamylated protein antibodies and the risk for arthritis2018 9,632,084'Anti-carbamylated protein antibodies and the risk for arthritis'2017 9,580,465'Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage'2017 9,340,598'Tissue protective peptides and uses thereof'2016 8,853,358'Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage'2014 8,716,245'Tissue protective peptides and uses thereof'2014 8,673,861'Tissue protective peptides and uses thereof'2014 8,404,226'Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs'2013 8,071,554'Tissue protective peptides and uses thereof'2011 7,767,643'Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs'2010 7,718,363'Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds'2010 7,645,733'Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions'2010 7,517,523'Anti-MIF antibodies'2009 7,410,941'Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin'2008 7,384,625'Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment'2008 7,345,019'Modulation of excitable tissue function by peripherally administered erythropoietin'2008 7,309,687'Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin'2007 7,090,861'Sustained release delivery systems for solutes'2006 7,022,721'Method and composition for rejuvenating cells, tissues, organs, hair and nails'2006 7,022,719'Preventing and reversing the formation of advance glycosylation endproducts'2006 6,998,238'Method for determining MIF content'2006 6,906,076'Compounds and methods of use to treat infectious diseases'2005 6,790,859'Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds'2004 6,777,557'Method and composition for rejuvenating cells, tissues organs, hair and nails'2004 6,713,050'Method and composition for rejuvenating hairs, nails, tissues, cells and organs by ex-vivo or immersive treatment'2004 6,689,777'Anti-malarial compounds, compositions and methods'2004 RE038330'Preventing and reversing advanced glycosylation endproducts'2003 6,649,797'Compounds and methods of use to treat infectious diseases'2003 6,645,493'Composition containing anti-MIF antibody'2003 6,615,842'Methods for removing nucleophilic toxins from tobacco smoke'2003 6,569,152'Sustained release delivery systems for solutes'2003 6,531,121'Protection and enhancement of erythropoietin-responsive cells, tissues and organs'2003 6,440,749'Method of treating certain indications associated with hyperglycemia'2002 6,419,927'Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages'2002 6,420,188'Screening assay for the identification of inhibitors for macrophage migration inhibitory factor'2002 6,410,598'Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis'2002 6,319,934'Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium compounds'2001 6,309,640'Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)'2001 6,297,253'Compounds and methods of use to treat infectious diseases'2001 6,248,787'Guanylhydrazones and their use to treat inflammatory conditions'2001 6,180,676'Guanylhydrazones and their use to treat inflammatory conditions'2001 6,174,526'Blood-borne mesenchymal cells'2001 6,119,701'Methods, agents and devices for removing nucleophilic toxins from tobacco and tobacco smoke'2000 6,121,300'Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts'2000 6,114,323'Methods for inhibiting the advanced glycosylation of proteins'2000 6,110,968'Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts'2000 6,103,234'Composition comprising an antibody to macrophage-derived inflammatory mediator (MIP-2)'2000 6,080,407'Diagnostic assays for MIF'2000 6,054,121'Modulation of immune responses in blood-borne mesenchymal cells'2000 6,046,309'Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'2000 6,030,615'Combination method for treating diseases caused by cytokine-mediated toxicity'2000 6,025,401'Method and agents for inhibiting protein aging'2000 6,022,900'Guanylhydrazones and their use to treat inflammatory conditions'2000 6,019,969'Composition comprising antibody to macrophage-derived inflammatory mediator (MIP-.alpha. 1 and MIP-1.beta.)'2000 6,008,255'Guanylhydrazones and their use to treat inflammatory conditions'1999 6,007,865'Reversing the formation of advanced glycosylation endproducts'1999 5,989,836'Method for measuring the binding sites for macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1999 5,962,245'Methods for detecting the presence of advanced glycosylation endproducts'1999 5,942,222'Methods of treating granulocyte-macrophage progenitor cell-derived blood cell dysfunction'1999 5,935,927'Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts'1999 5,891,341'Compositions and devices for partitioning advanced glycosylation endproducts, and methods of their use'1999 5,869,534'Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom'1999 5,863,535'Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1999 5,861,238'Methods for partitioning advanced glycosylation endproducts'1999 5,859,062'Guanylhydrazones and their use to treat inflammatory conditions'1999 5,855,882'Methods for inhibiting the cross-linking of advanced glycosylation endproducts'1999 5,854,000'Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts'1998 5,853,703'Preventing and reversing the formation of advanced glycosylation endproducts'1998 5,854,289'Guanylhydrazones and their use to treat inflammatory conditions'1998 5,852,009'Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon'1998 5,850,840'Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts'1998 5,852,174'Antibodies to liver derived receptors for advanced glycosylation endproducts and uses therefor'1998 5,849,794'Guanylhydrazones and their use to treat inflammatory conditions'1998 5,849,873'Macrophage-derived inflammatory mediator (MIP-1 .alpha. and MIP-1 .beta.)'1998 5,846,796'Blood-borne mesenchymal cells'1998 5,840,893'Compounds for treating infectious diseases'1998 5,840,305'Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity'1998 5,817,763'Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1998 5,811,075'Method and agents for removing advanced glycosylation endproducts'1998 5,804,446'Blood-borne mesenchymal cells'1998 5,801,200'Methods and materials for the diagnosis and treatment of conditions such as stroke'1998 5,780,615'Glycosylation of lipids and lipid-containing particles and diagnostic and therapeutic methods and materials derived therefrom'1998 5,770,571'Method and agents for inhibiting protein aging'1998 5,766,856'Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor'1998 5,760,186'Antibody to macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1998 5,753,684'Guanylhydrazones and their use to treat inflammatory conditions'1998 5,750,573'Guanylhydrazones and their use to treat inflammatory conditions'1998 5,741,484'Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1998 5,733,933'Methods and materials for the diagnosis and treatment of conditions such as stroke'1998 5,733,932'Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions'1998 5,733,524'Methods and materials for the diagnosis and treatment of conditions such as stroke'1998 5,717,074'Macrophage-derived inflammatory mediator (MIP-2)'1998 5,703,206'Macrophage inflammatory protein 2 (MIP-2)'1997 5,703,086'Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions'1997 5,700,466'Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor'1997 5,700,447'Methods and materials for the diagnosis and treatment of conditions such as stroke'1997 5,698,419'Monoclonal antibodies to cachectin/tumor necrosis factor and methods for preparing same'1997 5,656,261'Preventing and reversing advanced glycosylation endproducts'1997 5,654,186'Blood-borne mesenchymal cells'1997 5,650,147'Methods of stimulating granulocyte-macrophage progenitor cells'1997 5,620,983'Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions'1997 5,616,688'Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.)'1997 5,612,332'Di- and triaminoguanidines, and methods of use'1997 5,610,076'Method for detecting hemoglobin advanced glycosylation endproducts'1997 RE035465'Method and agents for removing advanced glycosylation endproducts'1997 5,599,984'Guanylhydrazones and their use to treat inflammatory conditions'1997 5,585,344'Liver-derived receptors for advanced glycosylation endproducts and uses thereof'1996 5,574,040'Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions'1996 5,514,676'Amino-benzoic acids and derivatives, and methods of use'1996 5,476,849'Methods for glycosylation inhibition using amino-benzoic acids and derivatives'1995 5,468,777'Method and agents for preventing and reversing the staining of teeth'1995 5,399,560'1,2,4-triazine products resulting from the inhibition of advanced glycosylation'1995 5,358,960'Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles'1994 5,356,895'1,4 piperizino inhibitors of non-enzymatic cross-linking of proteins'1994 5,334,617'Amino acids useful as inhibitors of the advanced glycosylation of proteins'1994 5,326,779'Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles'1994 5,318,982'Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles'1994 5,316,754'In vitro assay of mesangial cell-derived receptors for advanced glycosylation endproducts'1994 5,288,615'Methods for preparing proteins of altered structure'1994 5,272,176'Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use'1993 5,272,165'2-alkylidene-aminoguanidines and methods of use therefor'1993 5,262,152'Amidrazones and derivatives thereof'1993 5,258,381'2-substituted-2-imidazolines'1993 5,254,593'Compositions containing biguanides and derivatives thereof as inhibitors of nonenzymatic cross-linking'1993 5,243,071'2-alkylidene-aminoguanidines and methods of use therefor'1993 5,238,963'Method and agents for inhibiting protein aging'1993 5,221,683'Diaminopyridine compounds and methods of use'1993 5,218,001'Inhibitors of the advanced glycosylation of proteins and methods of use therefor'1993 5,202,424'Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof'1993 5,175,192'Inhibitors of the advanced glycosylation of proteins and methods of use therefor'1992 5,145,676'Method and agents for promoting wound healing'1992 5,145,975'Naphthoquinone derivatives'1992 5,140,048'Inhibitors of nonenzymatic cross-linking'1992 5,137,916'Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use'1992 5,130,324'2-alkylidene-aminoguanidines and methods of use therefor'1992 5,130,337'Amidrazones and derivatives thereof'1992 5,128,122'Method and agents for preventing staining of teeth'1992 5,128,360'Method and agents for inhibiting protein aging'1992 5,126,442'Advanced glycosylation endproducts and associated methods'1992 5,114,943'Amino-substituted pyrimidines, derivatives and methods of use therefor'1992 5,106,877'Aminoalcohol compounds in methods of use as inhibitors of the advanced glycosylation of proteins and methods of use therefor'1992 5,100,919'Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein'1992 5,096,703'Method and agents for preventing staining of teeth'1992 5,017,696'Advanced glycosylation end products and associated methods'1991 4,983,604'Inhibitors of nonenzymatic cross-linking'1991 4,978,684'Method and agents for preventing staining of teeth'1990 4,942,170'2-(substituted methylidene)-N-[3-[piperidin-1-yl]propyl]hydrazine carboximidamides useful as antiparasitics'1990 4,908,446'Inhibitors of nonenzymatic cross-linking'1990 4,900,747'Method and agents for removing advanced glycosylation endproducts'1990 4,822,776'Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)'1989 4,788,149'Proteolytic enzyme from blood-sucking nematodes and its uses as an anticoagulant as a vaccine and as an antithelminic agent'1988 4,761,368'Method and agents for measuring protein aging'1988 4,758,583'Method and agents for inhibiting protein aging'1988 4,731,323'Methods of measurement and detection employing photosensitive compositions and products'1988 4,705,845'Process for sulphation and phosphorylation of proteins and peptides'1987 4,665,192'2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole'1987 4,603,106'Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)'1986 4,534,894'Process for sulphation and phosphorylation of proteins and peptides'1985 4,469,681'Method and system for the controlled release of biologically active substances to a body fluid'1984 4,466,941'Photosensitive compositions and products'1984 4,462,989'Method and agents for arresting infection'1984 4,436,094'Monitor for continuous in vivo measurement of glucose concentration'1984 4,424,216'Method for the reduction of mucin viscosity'1984 4,405,606'Method for arresting fulminating infection'1983 4,371,374'Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine'1983 4,362,711'Blood cholesterol level reducing agent and method'1982 4,348,387'Method and system for the controlled release of biologically active substances to a body fluid'1982 4,330,299'Article and method for measuring glucose level in body fluids'1982 4,247,533'Hemoglobin A.sub.1c radioimmunoassay'1981

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1981–2001Patents assigned to UNIV ROCKEFELLER (78)· patent assignee history

1981–2014Based in New York, NY, US· patent location history

1982–2001Based in Flanders, NJ, US· patent location history

1990–2009Based in Shelter Island, NY, US· patent location history

1992–2006Patents assigned to ALTEON INC (27)· patent assignee history

1996–2003Patents assigned to PICOWER INST MED RES (48)· patent assignee history

2003–2013Patents assigned to KENNETH S WARREN INST INC (8)· patent assignee history

2003–2006Based in Sleepy Hollow, NY, US· patent location history

2011–2020Patents assigned to ARAIM PHARMACEUTICALS INC (8)· patent assignee history

2016–2020Based in La Jolla, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
UNIV ROCKEFELLER	78	1981–2001
PICOWER INST MED RES	48	1996–2003
ALTEON INC	27	1992–2006
ARAIM PHARMACEUTICALS INC	8	2011–2020
KENNETH S WARREN INST INC	8	2003–2013

Locations

Location	Patents	Span
Shelter Island, New York, US	107	1990–2009
New York, New York, US	20	1981–2014
Flanders, New Jersey, US	19	1982–2001
Sleepy Hollow, New York, US	8	2003–2006
La Jolla, California, US	4	2016–2020